Search alternatives:
significant time » significant threat (Expand Search), significant cause (Expand Search), significant gap (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), small decrease (Expand Search)
time based » home based (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant time » significant threat (Expand Search), significant cause (Expand Search), significant gap (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), small decrease (Expand Search)
time based » home based (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
161
-
162
-
163
-
164
-
165
-
166
Image_1_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.pdf
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
167
Image_2_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.pdf
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
168
Table_2_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
169
Table_3_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
170
Table_1_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180